Introduction

Urokinase is a thrombolytic medication used to dissolve blood clots in various medical conditions. It is widely used in deep vein thrombosis, pulmonary embolism, and stroke. Its mechanism directly targets fibrin, breaking down clots efficiently to restore blood flow.

• CAS Number: 9039-53-6
• Standards: In-House / IP / EP / BP

Applications

1. High-Efficiency Thrombolysis for Emergency Care

Urokinase rapidly dissolves blood clots by catalyzing the conversion of plasminogen to plasmin, which degrades fibrin-the structural backbone of clots. This ensures fast clot breakdown and helps prevent complications like myocardial infarction, ischemic stroke progression, and fatal pulmonary embolism.

2. User-Friendly Administration for Clinical Versatility

Administered via intravenous (IV) injection or infusion, urokinase requires no specialized equipment, allowing emergency departments, ICUs, and hospitals to start treatment promptly-critical for preserving organ function in urgent cases.

3. Superior Safety Profile with Reduced Bleeding Risk

Compared to other thrombolytic agents, urokinase minimizes disruption to systemic coagulation, lowering severe bleeding events like intracranial hemorrhage or gastrointestinal bleeding. This makes it suitable for vulnerable populations, including the elderly or patients with comorbidities.

4. Salvage Therapy for Refractory Cases

Urokinase is a crucial "rescue option" when conventional therapies fail, such as anticoagulants or antiplatelet drugs in acute ischemic stroke. It effectively breaks down resistant clots, reducing irreversible tissue damage and improving patient outcomes.

Summary

As a specialized thrombolytic API, urokinase offers rapid, targeted clot-dissolving efficacy, simplified clinical administration, enhanced safety with low bleeding risk, and value as a salvage therapy. It provides pharmaceutical manufacturers and clinical institutions with a high-performance raw material to develop life-saving medications, compliant with global quality standards.